Compare 8x8 Inc (EGHT) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Medpace Holdings Inc — how do they compare? 8x8 Inc trades at $2.02 (market cap $309.09M), while Medpace Holdings Inc trades at $598 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 54.7× 8x8 Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals.
| EGHT | MEDP | |
|---|---|---|
Market Cap | $309.09M | $16.90B |
Sector | Technology | Technology |
52-Week High | $2.76 | $620.59 |
52-Week Low | $1.59 | $393.42 |
Enterprise Value | $576.02M | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.01, down 10.27% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights AI platform expansion and partner program enhancements driving growth.
The outlook appears constructive with analyst consensus target of $3.13 representing 56% upside potential. Key risks include high debt levels and negative retained earnings, while catalysts include continued AI adoption and revenue growth acceleration toward profitability.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
